Showing results (511-520 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|February 16, 2026
Racial, ethnic, and regional disparities in HIV testing during the COVID-19 pandemic in the USA: a nationwide, retrospective, observational study using National Clinical Cohort Collaborative dataHaishan Yang, Duolan Han, Eric Hurwitz, et al.
The Lancet. HIV|October 24, 2025
Reducing HIV incidence and mortality: two sides of the same coin in the approach to ending AIDSJoseph N Jarvis, Peter Ehrenkranz, David S Lawrence, et al.
The Lancet. HIV|November 10, 2025
Projecting changes in demographics and causes of death in people with HIV in western Europe from 2025 to 2050: a mathematical modelling studyJulie Ambia, Ard van Sighem, Nikos Pantazis, et al.
The Lancet. HIV|September 27, 2025
A research framework to support re-engagement and continuous engagement in HIV careMarie-Claude C Lavoie, Elvin H Geng
The Lancet. HIV|June 1, 2020
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohortPilar Vizcarra, María J Pérez-Elías, Carmen Quereda, et al.
The Lancet. HIV|September 7, 2025
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trialJayne Ellis, Elisabetta Groppelli, Ronan Doyle, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
The Lancet. HIV|August 3, 2025
Probability of vertical HIV transmission: a systematic review and meta-regressionMagdalene K Walters, Michelle A Bulterys, Michael Barry, et al.
The Lancet. HIV|August 20, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trialShabir A Madhi, Anthonet L Koen, Alane Izu, et al.
The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.
Pageof 79